See the DrugPatentWatch profile for sylvant
When does Sylvant (siltuximab) patent protection expire?
The exact Sylvant patent expiration depends on which specific patent (and which country) is being referenced. “Sylvant” is associated with multiple intellectual-property filings, and different jurisdictions have different term calculations and extensions. Without the specific patent number(s) or the country/region (US, EP, UK, etc.), a single expiration date can’t be stated accurately.
How do you find the right Sylvant patent expiration date (US vs EU)?
Searchers usually narrow the question by:
- Identifying the market authorization holder and the medicine name (“Sylvant”) for the target country.
- Checking the relevant patent family in that country’s patent database.
- Checking for any regulatory extensions or supplementary protection mechanisms that can extend effective protection beyond the standard patent term.
If you tell me the country (for example, United States or European Union) and, if you have it, the patent number, I can help map it to the expiration date more precisely using the provided records.
Is Sylvant exclusivity the same as “patent expiration”?
No. “Patent expiration” and “exclusivity” are different concepts:
- Patents cover specific inventions and expire based on patent term (plus possible adjustments/terms).
- Regulatory exclusivity (often tied to approval data protection, marketing exclusivity, or orphan-related regimes) can limit generic or biosimilar competition even if some patents expire.
So the time when cheaper versions can enter depends on the mix of expiring patents and regulatory exclusivity in the relevant country.
What counts as a “biosimilar” risk for Sylvant?
Sylvant is an antibody therapy (not a small molecule). Competitive entry timelines in practice depend on:
- Whether a follow-on biologic qualifies as a biosimilar (or similar pathway product) in that jurisdiction.
- Which patents are still in force (and which are challenged or fall away).
- Any granted regulatory exclusivity/data protection in the relevant region.
If patents are still active, when can competitors launch anyway?
In many markets, competitors may still launch “at risk” if they believe patents won’t hold up in litigation or if specific patents are found not infringed/invalid. But absent a successful challenge, launches typically wait until relevant patents expire or are cleared.
What I need from you to give an exact expiration date
Reply with one of the following, and I’ll narrow to the exact expiration:
- Country/region (US, EP, UK, etc.)
- The patent number (or a link/name from a patent alert you saw)
- The drug label/holder you’re using as the reference (if known)
Sources: none provided in the prompt.